The Effect of Dulaglutide on Major Cardiovascular Events in Patients with Type 2 Diabetes: Researching Cardiovascular Events with a Weekly INcretin in Diabetes (REWIND)

Next Previous
Trial Profile

The Effect of Dulaglutide on Major Cardiovascular Events in Patients with Type 2 Diabetes: Researching Cardiovascular Events with a Weekly INcretin in Diabetes (REWIND)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Jan 2018

At a glance

  • Drugs Dulaglutide (Primary)
  • Indications Cardiovascular disorders; Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms REWIND
  • Sponsors Eli Lilly

    • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 19 Oct 2016 Planned End Date changed from 1 Apr 2019 to 1 Jul 2018.
    • 19 Oct 2016 Planned primary completion date changed from 1 Apr 2019 to 1 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top